How Ezetimibe Lowers Cholesterol
Ezetimibe reduces blood cholesterol by blocking its absorption in the small intestine, not by obstructing fatty food digestion itself. It targets dietary and biliary cholesterol taken up by enterocytes, lowering LDL cholesterol by 15-25% when used alone.[1]
Mechanism: Blocking NPC1L1 in the Intestine
Ezetimibe binds to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of intestinal cells. This transporter normally facilitates cholesterol uptake from mixed micelles in the gut lumen. By inhibiting NPC1L1, ezetimibe prevents cholesterol from entering enterocytes, allowing it to pass unabsorbed into feces. Fats and triglycerides digest normally via pancreatic lipases and bile salts, as ezetimibe spares these processes.[2][3]
Why It Doesn't Affect Fat Digestion
Fat digestion breaks triglycerides into monoglycerides and free fatty acids using lipases, independent of NPC1L1. Ezetimibe selectively inhibits cholesterol sterol absorption (about 50% reduction), leaving fat absorption (via CD36 and FATPs) intact. Clinical trials confirm no increase in steatorrhea or fat malabsorption.[4]
Role in Combination Therapy
Often paired with statins like simvastatin (Vytorin), ezetimibe adds incremental LDL reduction (up to 20%) by tackling intestinal absorption that statins miss. This complements HMG-CoA reductase inhibition in the liver.[1][5]
Common Patient Questions on Side Effects and Diet
No impact on digesting fatty meals—no bloating, diarrhea, or weight changes from fat malabsorption. Mild GI upset occurs in <5% of users. Dietary fat intake can continue unrestricted, though low-cholesterol diets enhance effects.[4]
[1]: FDA Label for Zetia (ezetimibe)
[2]: Nature Reviews Drug Discovery: Ezetimibe mechanism
[3]: Journal of Lipid Research: NPC1L1 inhibition
[4]: IMPROVE-IT Trial (NEJM)
[5]: DrugPatentWatch: Ezetimibe patents